CA2437480A1 - Methode de traitement des troubles du precurseur de la proteine .beta. amyloide - Google Patents

Methode de traitement des troubles du precurseur de la proteine .beta. amyloide Download PDF

Info

Publication number
CA2437480A1
CA2437480A1 CA002437480A CA2437480A CA2437480A1 CA 2437480 A1 CA2437480 A1 CA 2437480A1 CA 002437480 A CA002437480 A CA 002437480A CA 2437480 A CA2437480 A CA 2437480A CA 2437480 A1 CA2437480 A1 CA 2437480A1
Authority
CA
Canada
Prior art keywords
hmg
beta
coa reductase
reductase inhibitor
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002437480A
Other languages
English (en)
Inventor
Lawrence Friedhoff
Joseph Buxbaum
Edward I. Cullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2437480A1 publication Critical patent/CA2437480A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement et de prévention de troubles de la maturation de l'APP tels que la maladie d'Alzheimer et le syndrome de Down, consistant à administrer à un mammifère une quantité efficace d'un inhibiteur de la HMG-CoA réductase. Cette invention concerne également des méthodes de traitement et de prévention de troubles de la maturation de l'APP tels que la maladie d'Alzheimer et le syndrome de Down, fondées sur la réduction du cholestérol cellulaire chez un mammifère. Ces méthodes réduisent la quantité de A.beta. peptides ou ralentissent la formation de A.beta. ou augmentent la libération de A.beta. peptides chez un mammifère souffrant de la maladie d'Alzheimer ou du syndrome de Down.
CA002437480A 2001-02-05 2002-02-05 Methode de traitement des troubles du precurseur de la proteine .beta. amyloide Abandoned CA2437480A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26588601P 2001-02-05 2001-02-05
US60/265,886 2001-02-05
PCT/US2002/003256 WO2002062824A2 (fr) 2001-02-05 2002-02-05 Methode de traitement de troubles de la maturation du precurseur de la proteine ? amyloide

Publications (1)

Publication Number Publication Date
CA2437480A1 true CA2437480A1 (fr) 2002-08-15

Family

ID=23012272

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002437480A Abandoned CA2437480A1 (fr) 2001-02-05 2002-02-05 Methode de traitement des troubles du precurseur de la proteine .beta. amyloide

Country Status (3)

Country Link
EP (1) EP1366061A4 (fr)
CA (1) CA2437480A1 (fr)
WO (1) WO2002062824A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
CA2531227A1 (fr) 2003-07-03 2005-02-10 Lipid Sciences Inc. Procedes et appareil de creation de derives particulaires de hdl a taux de lipides reduit
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
ATE535614T1 (de) 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
CA3083194A1 (fr) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systemes et procedes pour amorcer des circuits fluides d'un systeme de traitement de plasma
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7397094A (en) * 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
WO1997048391A2 (fr) * 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methodes et compositions a base de r-ibuprofene
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
US5976817A (en) * 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US6172277B1 (en) * 1997-10-28 2001-01-09 The Miriam Hospital Non-transgenic rodent model of alzheimer's disease
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
EP1133699A1 (fr) * 1998-11-25 2001-09-19 Scios Inc. Prevention et traitement de troubles associes aux proteines amyloides
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法

Also Published As

Publication number Publication date
WO2002062824A3 (fr) 2002-11-21
WO2002062824A2 (fr) 2002-08-15
EP1366061A4 (fr) 2006-04-26
EP1366061A2 (fr) 2003-12-03

Similar Documents

Publication Publication Date Title
US20020107173A1 (en) Method of treating amyloid beta precursor disorders
AU780624B2 (en) Method of treating amyloid beta precursor disorders
CA2437480A1 (fr) Methode de traitement des troubles du precurseur de la proteine .beta. amyloide
AU2003206397B2 (en) Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
JP2013036996A (ja) アテローム性動脈硬化疾患に関する個人の危険性プロフィールを確認する手段
CZ293257B6 (cs) Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě
KR20240148350A (ko) 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
US7101879B2 (en) Treatments for neurotoxicity in Alzheimer's Disease
US20030105152A1 (en) Treatments for neurotoxicity in Alzheimer's disease
KR20190006515A (ko) App 의 정상 가공을 촉진하는 화합물
AU2002250013A1 (en) Method of treating amyloid ? precursor disorder
AU2005202965A1 (en) Method of treating amyloid beta precursor disorders
WO1997039754A1 (fr) Utilisation de prostaglandines pour traiter l'ataxie telangiectasie
RU2663460C2 (ru) Комбинированный препарат, содержащий валсартан и розувастатин кальция и способ его изготовления
TW201725038A (zh) 藉由曲線下面積（ａｕｃ）給與奧美沙坦（ｏｌｍｅｓａｒｔａｎ）之劑量的方法
US9989543B2 (en) Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
CN118903035A (zh) 一种头孢丙烯与丙磺舒组成的复方片剂及其制备方法
JP2026501945A (ja) ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む経口用薬学製剤
Sugaru et al. Articles in PresS. Am J Physiol Renal Physiol (May 17, 2005). doi: 10.1152/ajprenal. 00065.2005
US20080188538A1 (en) Methods of lowering glucose levels
Willerson et al. PROCLAIM.
CN101312728A (zh) 用于改善APOE4阴性病人认知功能的PPAR-γ激动剂
JP2003128582A (ja) アテローム性動脈硬化疾患に関する個人の危険性プロフィールを確認する手段

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued